摘要
目的：评价吉西他滨（GEM）与长春瑞滨（NVB）联合（GN方案）治疗对铂类方案耐药的中晚期非小细胞肺癌（non—small cell lungcancer，NSCLC）的疗效及毒副反应。方法：23例既往接受铂类治疗2周期以上无效的中晚期NSCLC患者，改为GN方案治疗。具体为吉西他滨1000mg／m^2静脉滴注d1、d8；长春瑞滨25mg／m^2静脉滴注d1、d8。结果：23例对铂类耐药的中晚期NSCLC患者经本方案治疗后，总有效率39．1％，中位生存期9．8个月，疾病进展时间为5．7个月，1年生存率45．8％，主要不良反应是血液学毒性，表现为Ⅰ－Ⅱ度白细胞减少78．3％，Ⅲ～Ⅳ度白细胞减少13．0％，Ⅰ～Ⅱ度血小板减少和红细胞减少分别为43．5％和30．4％；非血液学毒性包括Ⅰ－Ⅱ度的恶心、呕吐、局部静脉炎等。结论：GN方案对铂类方案耐药的中晚期NSCLC疗效较好，毒副反应可以耐受，值得在临床上推广和应用。
Objective： To value the the efficacy and toxicities of gemcitabine （ GEM ） associated with navelbine （ NVB ） （ GN protocol ） on treatment of patients with advanced non-small cell lung cancer （ NSCLC ） resistant to platinum. Methods： Twenty-three cases of NSCLC anciently treated with platinum for two cycles with no obvious therapeutic effect were treated with GN. The details on the therapy are as follows：GEM was taken through the intravenous dripping at 1 000 mg/m^2 on the day 1st and day 8th while NVB was taken through the intravenous dripping at 25 mg/m^2 on the day 1 st and day 8th. Results： These patients who were treated with GN were acquired 39.1% of the total effective rate, 9.8 months of the median survival time, 5.7 months of the illness advancing time and 45.8% of one-year survival rate. The major toxicity lies with the hematology,it is manifested by 78.3% of the decrease on the white cell Ⅰ-Ⅱ , 13.0% of the decrease on the white cell Ⅲ～Ⅳ ,43.5% of the Ⅰ-Ⅱ decrease on the platelet and 30.4% of anemia. The toxicity in the non-hematology includes vomiting, nausea and local phlebitis and so on. Conclusions：GN protocol with GEM associated with NVB has a superior therapeutic effect on advanced NSCLC resistant to Platinum with endurable side effects, which is worth popularizing and applying in the clinic.
出处
《蚌埠医学院学报》
CAS
2009年第7期601-603,共3页
Journal of Bengbu Medical College
关键词
肺肿瘤
癌
非小细胞肺
肿瘤/药物疗法
吉西他滨
长春瑞滨
lung neoplasms
cancer, non-small cell lung
neoplasms/drug therapy
gemcitabine
navelbine
